Noting that it is natural to prioritise COVID-19 vaccine distribution, Health Minister Harsh Vardhan on Thursday said healthcare workers and people aged above 65 will be early recipients when a vaccine becomes available. The vaccines' full safety data hasn't yet been published.
The Phase III trials of the ChAdOx1 nCov-2019 vaccine are ongoing, with early efficacy readings possible in the coming weeks.
United Kingdom authorities have placed orders for 100 million doses of the vaccine - enough to vaccinate most of the population - should it receive regulatory approval.
AstraZeneca has committed to making the vaccine at greater volumes across a wider geographic footprint than its Western peers.
"Negotiations are also underway with Pfizer, which can deliver up to 25 million doses of vaccines to Turkey", Koca said, as cited by the TRT state broadcaster.More news: IO Interactive Reveals New 007 Game With Teaser Trailer
"The report on the AstraZeneca and University of Oxford vaccine was less likely to move the dial as, unlike the other major vaccine updates so far, there was no detail on its efficacy", said AJ Bell investment director Russ Mould.
Immunogenicity was similar across age groups after a boost vaccination.
Governments are expected to give priority to older adults in rollouts of vaccines, which could start in limited quantities before the end of this year.
The Pfizer vaccine was found to be 95 per cent effective, based on last-stage trials. Those positive outcomes were present in all age groups given low and standard doses.
The study involved 560 adults, including 240 over the age of 70. Most were white nonsmokers.More news: Meet Miles Morales, the New, Portland-Born Spider-Man
Other Covid-19 vaccines have also been shown to generate immune responses in older adults, but it can be hard to compare results between different studies.
The earlier findings on the vaccine had shown the Oxford vaccine generated a robust immune system among people aged 18-55.
Adverse reactions were mild - injection-site pain and tenderness, fatigue, headache, feverishness and muscle pain - but more common than seen with the control vaccine.
Phases 1 and 2 of clinical trials were held in April, the third is underway.More news: Apple reveals MagsSafe Duo Charger is limited to 11 or 14 Watts